Daré Bioscience, Inc.DARENASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, above historical average, modest growth trend.
Left:
||||
Year-over-year operating income growth rate
Latest
4.07%
↑ 106% above average
Average (39q)
-66.46%
Historical baseline
Range
High:104.58%
Low:-1957.50%
CAGR
+8.5%
Consistent expansion
| Period | Value |
|---|---|
| Q3 2025 | 4.07% |
| Q2 2025 | 16.44% |
| Q1 2025 | 14.98% |
| Q4 2024 | -15.10% |
| Q3 2024 | 36.39% |
| Q2 2024 | -22.20% |
| Q1 2024 | -16.46% |
| Q4 2023 | 38.41% |
| Q3 2023 | 6.60% |
| Q2 2023 | -7.24% |
| Q1 2023 | 48.27% |
| Q4 2022 | -127.01% |
| Q3 2022 | -1957.50% |
| Q2 2022 | 104.58% |
| Q1 2022 | 11.97% |
| Q4 2021 | 24.67% |
| Q3 2021 | -38.26% |
| Q2 2021 | -19.10% |
| Q1 2021 | 8.85% |
| Q4 2020 | -11.33% |
| Q3 2020 | -6.40% |
| Q2 2020 | -67.51% |
| Q1 2020 | -10.19% |
| Q4 2019 | -12.92% |
| Q3 2019 | 14.14% |
| Q2 2019 | -29.16% |
| Q1 2019 | -4.19% |
| Q4 2018 | -12.85% |
| Q3 2018 | 27.67% |
| Q2 2018 | 52.78% |
| Q1 2018 | 16.00% |
| Q4 2017 | -585.60% |
| Q3 2017 | -177.71% |
| Q2 2017 | -110.53% |
| Q1 2017 | 94.94% |
| Q4 2016 | 52.36% |
| Q3 2016 | 8.08% |
| Q2 2016 | 20.12% |
| Q1 2016 | -28.51% |
| Q4 2015 | 0.17% |